Lysando AG
Biopharmaceutical company developing engineered antimicrobial protein therapeutics and topical formulations for management of bacterial infections. Uses AI-driven protein design and a proprietary construct database to develop molecules that target resistant and persistent bacteria and biofilms. Operates R&D and production facilities and engages in partnerships and clinical/compassionate-use applications in wound care and dermatology.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Engineered antimicrobial protein platform (Artilysin technology)
Platform of precision-designed protein molecules intended to selectively reduce pathogenic bacteria, including resistant and persistent species, and to act within biofilms while preserving beneficial microbiome components.
Medolysin wound spray
Topical two-solution wound spray formulation designed to form a protective film, support a moist wound environment, reduce bacterial load (separate solutions targeting gram-negative and gram-positive bacteria), and promote wound healing.
Engineered antimicrobial protein platform (Artilysin technology)
Platform of precision-designed protein molecules intended to selectively reduce pathogenic bacteria, including resistant and persistent species, and to act within biofilms while preserving beneficial microbiome components.
Medolysin wound spray
Topical two-solution wound spray formulation designed to form a protective film, support a moist wound environment, reduce bacterial load (separate solutions targeting gram-negative and gram-positive bacteria), and promote wound healing.
Expertise Areas
- Antimicrobial protein therapeutics
- Microbiome modulation and microbiome-friendly approaches
- Wound care and dermatology therapeutics
- AI-driven protein design and computational protein engineering
Key Technologies
- AI-driven protein design
- Protein engineering
- Engineered antimicrobial proteins
- Topical spray wound formulations
News & Updates
Press release announcing appointment of Tim McCaffery to the company's advisory board.
Press release describing a donation of topical wound spray to Ukrainian hospitals in collaboration with a non-profit organization.
Press release announcing appointment of Jorge Cortell to the advisory board.
Company reports protection of its platform by hundreds of national patents and applications.
Reported case series and study data (brochures cite two studies and 72 patients) documenting initiation of wound healing and complete healing in reported cases following topical application.
Press release announcing appointment of Tim McCaffery to the company's advisory board.
Press release describing a donation of topical wound spray to Ukrainian hospitals in collaboration with a non-profit organization.
Press release announcing appointment of Jorge Cortell to the advisory board.
Company reports protection of its platform by hundreds of national patents and applications.
Reported case series and study data (brochures cite two studies and 72 patients) documenting initiation of wound healing and complete healing in reported cases following topical application.